These and other results largely failed to impress experts, many of whom said the drug would need to have far bigger benefits to outweigh its price tag and potential harms. “It seems more incremental than blockbuster,” said Dr. Taison Bell, a critical care physician at the University of Virginia, who was involved in the clinical trial. Although Bell described baricitinib as a reasonable addition to the COVID treatment toolbox and even deserving of an emergency approval, “I don’t think it’s a game changer,” he said.